Small Molecule Modulators of



The immune system is made up of two arms that work together as the body’s defence - innate and adaptive. The innate immune system is the body’s first line of defence. It has the capability to recognise and destroy various pathogens, initiate wound healing processes, recognise and clear damaged components. Avammune is developing highly potent and specific small molecule modulators of the innate immune system with the potential to target a variety of diseases.


Current immunotherapies such as checkpoint inhibitors target the adaptive immune system. These therapies despite their success are limited by efficacy in “hot tumors” or poor immune memory. Innate immunity modulators can turn “cold tumors” to responsive “hot tumors” and also reduce cancer recurrence by strengthening immunological memory. These modulators can be effectively combined with a variety of therapeutic modalities such as checkpoint inhibitors, chemotherapy, radiotherapy, and oncolotyic viruses.


Various autoimmune and inflammatory diseases are caused by an overactive innate immune system. By specifically targeting these pathways we have the potential to act upstream from where inflammation starts, thereby allowing us to develop safer and more effective drugs for these diseases.



Mr. Arun B Papaiah

Founder and Chief Executive Officer

Arun is the Founder and CEO at Avammune Therapeutics. He previously co-founded Aten Porus Lifesciences and Oraxion Therapeutics, R&D companies focused on drug discovery. Arun was instrumental in the option agreement of Oraxion’s technology platform to a US based biotech company for $125 MM.

Arun holds an MBA from the Royal Melbourne Institute of Technology (Australia), and a Bachelor of Science degree from Christ University (India). Arun has over 10 years of experience as an entrepreneur in various aspects of business including Finance, Operations, Technology transfer and Business development.

Dr. Aditya Kulkarni

Founder and Chief Scientific Officer

Aditya is the Founder and CSO at Avammune Therapeutics. He previously co-founded Aten Porus Lifesciences and Oraxion Therapeutics, R&D companies focused on drug discovery. Aditya is the inventor of Oraxion’s technology platform that was eventually licensed to a US based biotech company for $125 MM. He has co-authored >15 papers and filed several international patents in the areas of nucleic acid delivery, Niemann-Pick Type C therapeutics, and drug discovery.

He has been a recipient of scholarships during his Masters and PhD and was also awarded the H. C. Brown Award for Outstanding Organic Research at Purdue University in June 2012. Aditya has a PhD in Bioorganic Chemistry from Purdue University (USA), MS in Chemical Biology from Leeds University (UK), and B.Sc in Chemistry from Christ University (India).

Mr. Srinivasan Namala

Founder and Director

Srinivasan is the Founder and Director at Avammune Therapeutics. He previously co-founded Aten Porus Lifesciences an Oraxion Therapeutics, both R&D companies focusesd on drug discovery. He is currently serving as the CEO of Porus Labs, a chemical manufacturing conglomerate serving customers across India, US, and Europe. Srinivasan has over 15 years of experience in varied aspects of business including technology transfer, SCM, Business Development and Finance. Srinivasan has an MS in Pharmaceutics from Northeastern University (USA), and B.Pharm from BITS Pilani (India).

Srinivasan has over 15 years of experience in varied aspects of business including technology transfer, SCM, Business Development and Finance. Srinivasan has an MS in Pharmaceutics from Northeastern University (USA), and B.Pharm from BITS Pilani (India).


Dr. Manoj Desai

Dr. Manoj Desai began his professional career in the pharmaceutical industry at Pfizer Inc,Central Research Division, Groton, CT (1986-1994) before moving to Chiron Corporation (1994-2003) as Director of medicinal chemistry. In October 2003, he was appointed Vice President of medicinal chemistry at Gilead Sciences. His research efforts at Gilead led to the discovery of cobicistat which is one of components of Stribild® that was approved by FDA for the treatment of HIV infection.

He is co-inventor on patents of cobicistat and ledipasvir. Cobicistat has been coformulated in four approved therapies for the treatment of HIV: Stribild® and Genvoya® (marketed by Gilead), Prezcobix® (marketed by Johnson & Johnson), Evotaz® (marketed by Bristol-Myers Squibb). Ledipasvir is a part of two-drug regimen in Harvoni® for curing Hepatitis C virus. Dr. Desai has 10 marketed drugs and 6 clinically approved NCEs and 8 drugs in clinical development. He has worked on >40 biological targets and >55 small molecule drugs recommended for clinical development. He has >60 publications in peer-reviewed journals and >25 issued patents.

Prof. Jean-François Paquin

Prof. Jean-François Paquin studied chemistry at the Université Laval where he graduated with a BSc degree. In 2004, he received his PhD degree under the supervision of Professor Mark Lautens at the University of Toronto (Canada). After a postdoctoral stay in Professor Erick M. Carreira’s lab at the ETH Zürich (Switzerland), he was appointed assistant professor in 2005 at the Université Laval in Quebec City (Canada) as a Tier 2 Canada Research Chair in Organic and Medicinal Chemistry (2005–2010).

In 2010, he was promoted to associate professor and his Canada Research Chair in Organic and Medicinal Chemistry was renewed (2010–2015). In June 2014, he was promoted to full professor. His current research interests include organofluorine chemistry, organic synthesis, catalysis, and medicinal chemistry. He has co-authored > 80 papers and received many prizes including the Keith Fagnou Award from the Canadian Society for Chemistry and a Research Fellowship from the Alexander von Humboldt Foundation.

Dr. David James Pinato

Dr David J. Pinato is a Clinician Scientist and Consultant Medical Oncologist at the Department of Surgery and Cancer at Imperial College, London. David leads a translational research program focusing on the early clinical implementation of novel experimental anticancer therapies to the clinic, with particular emphasis on anti-cancer immunotherapy. David completed his research training being awarded a Masters of Research in Translational Medicine and a Ph.D. in Clinical and Experimental Medicine and gained clinical skills attending the University Hospital in Zürich, the Medical University in Vienna and the University of Ioannina in Greece.

He was elected member of the Royal College of Physicians (MRCP) in 2014. David's research efforts on biomarker discovery have been recognized with the prestigious Merit Award from the American Society of Clinical Oncology (ASCO) three times in 2016, 2017, 2019 as well as a fourth Merit Award jointly awarded by ASCO and by the Society for Immunotherapy of Cancer (SITC) in 2019. David was also awarded a prize by the British Society of Pharmacology in 2018 and the Sylvia Lawler Prize in Oncology from the Royal Society of Medicine in 2016. He has been awarded the European School of Oncology fellowship in 2008 and the Fulbright Visiting Research Scholar Fellowship for 2010/2011.

Prof. Jan Rehwinkel

Prof. Jan Rehwinkel is Professor of Innate Immunology at the University of Oxford, UK. His laboratory is part of the MRC Human Immunology Unit and the MRC Weatherall Institute of Molecular Medicine. Jan's research dissects nucleic acid sensing by innate receptors in the context of virus infection, autoinflammatory disease and cancer. Jan is interested in the molecular mechanisms underlying host-pathogen interactions. His work lies at the intersection of immunology, virology and molecular biology.

After undergraduate training in biology at the University of Heidelberg (Germany), Jan joined the European Molecular Biology Laboratory (EMBL) as a PhD student under the supervision of Elisa Izaurralde. As a postdoctoral fellow, he joined the group of Caetano Reis e Sousa, then at the Cancer Research UK London Research Institute (London, UK). In 2012, Jan moved to the University of Oxford, UK, to establish his independent research group. Jan's work is funded by the MRC, Wellcome Trust, Lister Institute and European Union.

Prof. James Vince

Assoc. Prof James Vince completed undergraduate studies (Biochemistry major) and a PhD in parasitology (Professor Macolm McConville) at The University of Melbourne in 2005. He subsequently undertook post-doctoral research on cell death with Professor John Silke (La Trobe University) and inflammasome biology with Jurg Tschopp (Switzerland). In 2013 he was appointed as a laboratory head at The Walter and Eliza Hall Institute of Medical Research (Australia).

His research program has made discoveries into the regulation of cell death-induced inflammation in infections, rare hereditary conditions (e.g. XIAP deficiency) and sterile diseases (e.g. endotoxic shock, arthritis), including the identification of potential treatments using clinically relevant cell death drugs or physiological molecules. He has published more than 70 highly cited papers (Thomson Reuters Citation Award) and is an inventor on 7 patent applications related to cell death-induced inflammation.


Feel free to email us if you are interested in the project and you want to know more, or to just say hello!
Philadelphia, PA.